Pharma major Lupin announced the exclusive launch of its Ranolazine Extended-Release (ER) Tablets, 500mg and 1000mg.
Lupin’s Ranolazine ER Tablets, 500mg and 1000mg are a generic version of Gilead Sciences, Inc.’s Ranexa ER Tablets, 500mg and 1000mg. Ranolazine is indicated for the treatment of chronic angina.
Ranolazine ER Tablets, 500mg and 1000mg had an annual sales of approximately USD 945 million in the US (IQVIA MAT December 2018).
Commenting on the launch, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are excited about the launch of generic Ranolazine as an exclusive generic in the US. This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics. Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to market.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company in terms of market capitalization (28th December 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th September 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT December 2018); 3rd largest Indian pharmaceutical company by global revenues (30th September 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT December 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT December 2018).
For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit https://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225
Arvind Bothra
Head – Investor Relations
Email:arvindbothra@lupin.com
Ph: +91-22-66408237
*Safe Harbor Statement
Ranexa® is a registered trademark of Gilead Sciences, Inc.
